Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DR. BOND who wrote (5596)	2/22/1998 2:36:00 PM
From: go_bucks	Respond to of 23519

Dear Dr. Bond: What are some of the other factors? What about dosage? The earlier prescriptions were mostly 250 mg ones? Now the best seller is the 1000mg ones.. Also the # of new prescriptions over 1997 have to come under scrutiny - the numbers may be exaggerated a bit at first because a patient could only buy 250 mg muse? Finally I think it would make sense for the mgmt to allocate the drugs to new patients rather than repeat customers - the repeat customers already know this is effective and when they are told they can't get refills because of supply constraint - they would go: wow this thing is so damn hot... too bad I didn't order more last time... when I can finally get my hands on them I'm going to stock up! Wheraz new customers, w/o knowing how effective MUSE is.. might turn to other therapy if they can't get to try MUSE out. Comments? Charlie

To: DR. BOND who wrote (5596)	2/22/1998 9:18:00 PM
From: MissLil	Respond to of 23519

It might be interesting to see some comparison data for other medications that are taken on a chronic basis. For instance, what are the "new scripts" and the "refills" on Prozac or Tenormin. Both of these are much more well established medications and one would expect them to have a higher refill/new ratio in any case. Would it be difficult for you to get these numbers?